enVVeno Medical Stock (NASDAQ:NVNO)

Ownership Financials Chart

Previous Close

$2.25

52W Range

$2.03 - $6.48

50D Avg

$2.95

200D Avg

$3.81

Market Cap

$41.03M

Avg Vol (3M)

$97.40K

Beta

1.04

Div Yield

NVNO Company Profile

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 31, 2018

Website

NVNO Performance

NVNO Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-23.83M	$-25.24M	$-24.93M
Net Income	$-21.82M	$-23.52M	$-24.30M
EBITDA	$-23.83M	$-25.02M	$-24.51M
Basic EPS	$-1.27	$-1.91	$-2.16
Diluted EPS	$-1.27	$-1.91	$-2.16

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
TMCI	Treace Medical Concepts, Inc.
AXGN	AxoGen, Inc.
LUNG	Pulmonx Corporation
KIDS	OrthoPediatrics Corp.
IRIX	IRIDEX Corporation
LNSR	LENSAR, Inc.
RXST	RxSight, Inc.
SSKN	STRATA Skin Sciences, Inc.
TNON	Tenon Medical, Inc.
LIVN	LivaNova PLC
SRDX	Surmodics, Inc.
AIMD	Ainos, Inc.
OFIX	Orthofix Medical Inc.